entertainment -WSS

entertainment

author：leisure time 2025-09-30 22:10:33 - browse：7

Intellia Therapeutics said Sunday that the first 10 patients to receive a CRISPR-based treatment for hereditary angioedema, a genetic disease, saw their swelling attacks — the condition’s hallmark symptom — virtually eliminated for an average of 20 months and counting.

The attacks were reduced by an average of 98%. One patient has remained attack-free for 26 months. Two patients who suffered particularly frequent attacks, experiencing 14 and 16.8 per month, respectively, have now gone more than 20 months since their last attack.

No patient has had an attack in the last 11 months of follow-up, according to the data presented at the European Academy of Allergy and Clinical Immunology Congress. All side effects were either grade 1 or 2 on a 5-grade scale.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： Acelyrin, a rare IPO success, stumbles in its first big test

entertainment

hotspot

WSS

Readout LOUD podcast: ALS dilemma, first MASH drug, and more

Why depression after traumatic brain injury is distinct

PEPFAR is under serious threat — and so is global health

Generate Biomedicines machine learning biotech raises $273M

HHS secretary Becerra pressed on Change HealthCare cyberattack

Private equity could exacerbate cardiology's overuse problem, experts fear

entertainment

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Wikipedia

Cancer drug shortages should be causing more outrage

Food makers tried to stack nutrition panel with preferred experts

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Readout Newsletter: Bristol, Sangamo, Gilead, and more

Affirmative action in medical school literally saved lives

Amylyx ALS drug fails trial: Relyvrio patients react with fear, worry

New air purifier tech could be key to improving indoor air quality

UCLA team creates talking throat patch for voice disorders

Cancer drug shortages should be causing more outrage

UCLA team creates talking throat patch for voice disorders

hotspot

Why depression after traumatic brain injury is distinct

How many hemophilia patients actually want gene therapy?

HHS secretary Becerra pressed on Change HealthCare cyberattack

PEPFAR is under serious threat — and so is global health

Will the IRA bring competition to the biologics market?

PEPFAR is under serious threat — and so is global health

entertainment

focus

hotspot

leisure time